PR Newswire
LAS VEGAS, Feb. 17, 2026
The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.
LAS VEGAS, Feb. 17, 2026 /PRNewswire/ — Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Juvenile Idiopathic Arthritis Market Summary
- According to DelveInsight’s analysis, the market size for juvenile idiopathic arthritis was found to be USD 2.3 billion in the 7MM in 2025.
- The United States accounted for the largest juvenile idiopathic arthritis treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- The total prevalent cases of JIA in the 7MM were approximately 142K in 2025 and are projected to increase to around 173K by 2036.
- Leading juvenile idiopathic arthritis companies, such as Bristol-Myers Squibb (NYSE: BMY), UCB Biopharma (EBR: UCB), Novartis (SWX: NOVN), and others, are developing new juvenile idiopathic arthritis treatment drugs that can be available in the juvenile idiopathic arthritis market in the coming years.
- The promising juvenile idiopathic arthritis therapies in clinical trials include Deucravacitinib (SOTYKTU), Bimekizumab (BIMZELX), MAS825, and others.
- In Japan, the maximum market share is expected to be captured by adalimumab in 2036.
Discover which regions are driving the fastest JIA market growth @ https://www.delveinsight.com/sample-request/juvenile-idiopathic-arthritis-jia-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Juvenile Idiopathic Arthritis Market
- Rising Prevalence of JIA: According to DelveInsight analysis, the total prevalent cases of JIA in the 7MM were 141,800 in 2025 and are projected to increase to around 173,000 by 2036 over the forecast period, reflecting a CAGR of 1.8%.
- Advancements in Therapeutics: Biologic therapies and targeted treatments (e.g., IL-6 inhibitors and JAK inhibitors) are transforming disease management, improving remission rates and patient quality of life.
- Launch of Emerging JIA Drugs: The dynamics of the JIA market are expected to change in the coming years due to the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others.
Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, said that the JIA market is evolving as treatment focus shifts from broad-spectrum biologics to more targeted therapies, with JAK inhibitors and IL-targeted agents driving adoption due to their favorable efficacy, safety, and expanded pediatric indications.
Juvenile Idiopathic Arthritis Market Analysis
- The JIA market is undergoing a significant shift after years of dependence on conventional immunosuppression and stepwise empiric treatment.
- This shift reflects the approval and expanding use of targeted therapies such as upadacitinib (RINVOQ) and sarilumab (KEVZARA), which validate cytokine- and pathway-specific strategies and accelerate innovation across the evolving JIA pipeline.
- Upadacitinib (RINVOQ), as an advanced JAK inhibitor, demonstrates meaningful clinical benefit in pediatric inflammation control, reinforces confidence in precision immunomodulation, and is expected to stimulate further R&D and investment across the JIA treatment landscape.
- With emerging targeted and biologic agents such as deucravacitinib, bimekizumab, and MAS825, the therapeutic evolution in JIA mirrors trends seen in other immune-mediated and rare inflammatory diseases, where early targeted approvals lead to broader expansion.
- The largest market remains the United States, supported by higher diagnosis rates, earlier biologic adoption, and stronger uptake of innovative therapies compared with the EU4, the United Kingdom, and Japan.
- Overall, first-in-class launches, improved genetic testing, and rising awareness are expected to drive steady 7MM market growth through 2036.
Juvenile Idiopathic Arthritis Competitive Landscape
Some of the JIA drugs in the clinical trial landscape include SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others.
Bristol-Myers Squibb’s SOTYKTU is an oral, highly selective TYK2 inhibitor that works through a unique allosteric mechanism, marking it as part of a new category of small-molecule treatments. It is the first therapy of its kind to undergo clinical evaluation across several immune-mediated conditions. Developed by Bristol Myers Squibb, the drug is engineered to precisely target TYK2 and block signaling driven by IL-23, IL-12, and type I interferons, pathways that are central to many immune-related diseases. Its strong selectivity comes from binding to TYK2’s regulatory domain, leading to allosteric suppression of TYK2 function and its downstream signals. At levels relevant to treatment, it inhibits TYK2 specifically without affecting JAK1, JAK2, or JAK3.
UCB Biopharma’s Bimekizumab is a humanized IgG1 monoclonal antibody designed to selectively neutralize both IL-17A and IL-17F, two cytokines that play major roles in driving inflammation. Currently, the drug is in phase III clinical trials.
The anticipated launch of these emerging therapies are poised to transform the juvenile idiopathic arthritis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the juvenile idiopathic arthritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which new or emerging therapies are expected to shape the JIA market @ Juvenile Idiopathic Arthritis Drugs
Recent Developments in the Juvenile Idiopathic Arthritis Market
- In September 2025, AbbVie submitted a filing in Japan for label expansion of upadacitinib for an additional indication of pJIA inadequately controlled with existing treatments, indicating work toward broader global availability for this indication beyond the US.
- In July 2025, the FDA accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis. The FDA has assigned a PDUFA goal date of March 6, 2026.
What is Juvenile Idiopathic Arthritis?
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition that causes persistent joint inflammation in children and adolescents, typically under the age of 16. In JIA, the immune system mistakenly attacks the body’s own tissues, leading to symptoms such as joint pain, swelling, stiffness, and reduced mobility. These symptoms can vary from mild to severe and may affect one joint or multiple joints. Although the exact cause is unknown, a combination of genetic and environmental factors is likely contributing. Early diagnosis and treatment are important for managing symptoms, preventing joint damage, and supporting healthy growth and development.
Juvenile Idiopathic Arthritis Epidemiology Segmentation
The juvenile idiopathic arthritis epidemiology section provides insights into the historical and current juvenile idiopathic arthritis patient pool and forecasted trends for the leading markets. In the US, approximately 34K diagnosed JIA patients in 2025 were male, whereas 66% female. This sex difference is attributed to females’ greater susceptibility to developing JIA, whereas the onset in males tends to occur later.
The juvenile idiopathic arthritis treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Total Prevalent cases of JIA
- Subtype-specific Prevalent Cases of JIA
- Gender-specific Prevalent Cases of JIA
- Treatment Eligible Cases of JIA
Juvenile Idiopathic Arthritis Market
Report Metrics
Details
Study Period
2022-2036
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United
Kingdom, and Japan].
Juvenile Idiopathic Arthritis Market
CAGR 5.6 %
Juvenile Idiopathic Arthritis Market
Size in 2025
USD 2.3 Billion
Key Juvenile Idiopathic Arthritis Bristol-Myers Squibb (NYSE: BMY), UCB Biopharma (EBR: UCB), Novartis (SWX: NOVN),
Companies AbbVie (NYSE: ABBV), Sanofi (EPA: SAN), Regeneron Pharmaceuticals (NASDAQ: REGN),
Janssen Pharmaceutical, Eli Lilly (NYSE: LLY), Sobi (STO: SOBI), Pfizer (NYSE:
PFE), and others
Key Juvenile Idiopathic Arthritis Deucravacitinib (SOTYKTU), Bimekizumab (BIMZELX), MAS825, RINVOQ, KEVZARA,
Therapies TREMFYA, COSENTYX, ORENCIA, CIMZIA, ILARIS, SIMPONI ARIA, OLUMIANT, TALTZ,
KINERET, XELJANZ, and others
Scope of the
Juvenile Idiopathic Arthritis
Market Report
- Therapeutic Assessment: Juvenile Idiopathic Arthritis current marketed and emerging therapies
- Juvenile Idiopathic Arthritis Market Dynamics: Key Market Forecast Assumptions of Emerging Juvenile Idiopathic Arthritis Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Juvenile Idiopathic Arthritis Market Access and Reimbursement
Download the report to understand who are the top pharmaceutical companies in juvenile idiopathic arthritis @ Juvenile Idiopathic Arthritis Market Analysis
Table of Contents
1
Juvenile Idiopathic Arthritis Market Key Insights
2
Juvenile Idiopathic Arthritis Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
JIA Market Overview at a Glance
6.1 Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2 Market Share (%) Distribution of JIA By Therapies in the 7MM, in 2025
6.3 Market Share (%) Distribution of JIA By Therapies in the 7MM, in 2036
7
Disease Background and Overview
7.1
Introduction
7.2
Types
7.3
Symptoms
7.4
Causes
7.5
Pathophysiology
7.6
Diagnosis
7.7
Treatment
8
Treatment Guidelines
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationale
9.3
Diagnosed Prevalent Cases of JIA in the 7MM
9.4
The United States
9.4.1 Total Diagnosed Prevalent Cases of JIA in the United States
9.4.2 Subtype-specific Diagnosed Prevalent Cases of JIA in the United
States
9.4.3 Gender-specific Diagnosed Prevalent Cases of JIA in the United
States
9.4.4
Treatment Eligible Cases of JIA in the United States
9.5
EU4 and the UK
9.6
Japan
10
Juvenile Idiopathic Arthritis Patient Journey
11
Marketed Juvenile Idiopathic Arthritis Therapies
11.1
Key Cross Competition
11.2
Upadacitinib (RINVOQ): AbbVie
11.2.1
Drug Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Summary of Pivotal Trials
11.2.5
Clinical Development
11.2.5.1
Clinical Trial Information
11.2.6
Analyst Views
11.3
Sarilumab (KEVZARA): Sanofi/Regeneron Pharmaceuticals
11.4
Guselkumab (TREMFYA): Janssen Pharmaceutical
11.5
Secukinumab (COSENTYX): Novartis
11.6
Abatacept (ORENCIA): Bristol-Myers Squibb
11.7
Certolizumab pegol (CIMZIA): UCB Biopharma
11.8
Canakinumab (ILARIS): Novartis
11.9
Golimumab (SIMPONI ARIA): Janssen Pharmaceutical
11.1
Baricitinib (OLUMIANT): Eli Lilly
11.11
Ixekizumab (TALTZ): Eli Lilly
11.12
Anakinra (KINERET): Sobi
11.13
Tofacitinib (XELJANZ): Pfizer
12
Emerging Juvenile Idiopathic Arthritis Drugs
12.1
Key Cross Competition
12.2
Deucravacitinib (SOTYKTU): Bristol-Myers Squibb
12.2.1
Drug Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.3.1
Clinical Trials Information
12.2.4
Analyst Views
12.3
Bimekizumab (BIMZELX): UCB
12.4
MAS825: NOVARTIS
13
JIA Market: 7MM Analysis
13.1
Key Findings
13.2
Juvenile Idiopathic Arthritis Market Outlook
13.3 Key Juvenile Idiopathic Arthritis Market Forecast Assumptions
13.4
Conjoint Analysis
13.5
Total Market Size of JIA in the 7MM
13.6
Total Market Size of JIA by Therapies in the 7MM
13.7
The United States Juvenile Idiopathic Arthritis Market
13.7.1
Total Market Size of JIA in the United States
13.7.2
Total Market Size of JIA by Therapies in the United States
13.8
EU4 and the UK Juvenile Idiopathic Arthritis Market
13.9
Japan Juvenile Idiopathic Arthritis Market
14
Juvenile Idiopathic Arthritis Market Unmet Needs
15
Juvenile Idiopathic Arthritis Market SWOT Analysis
16
KOL Views on JIA
17 Juvenile Idiopathic Arthritis Market Access and Reimbursement
17.1
The United States
17.2
EU4 and the UK
17.3
Japan
17.4 Summary and comparison of Market Access and Pricing Policy
Developments in 2025
17.5
Market Access and Reimbursement of JIA Therapies
18
Bibliography
19
Juvenile Idiopathic Arthritis Market Report Methodology
Related Reports
Juvenile Idiopathic Arthritis Clinical Trial Analysis
Juvenile Idiopathic Arthritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JIA companies, including Bristol-Myers Squibb, UCB Biopharma, Novartis, AbbVie, Sanofi, Regeneron Pharmaceuticals, Janssen Pharmaceutical, Eli Lilly, Sobi, Pfizer, and others.
Systemic Juvenile Idiopathic Arthritis Market
Systemic Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key systemic juvenile idiopathic arthritis companies including Novartis, Roche, Genentech, AbbVie, Pfizer, Eli Lilly and Company, Bristol Myers Squibb, Johnson & Johnson, Merck & Co., UCB, Sanofi, and others.
Rheumatoid Arthritis Market
Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies including Cyxone, Taiho Pharmaceutical, AstraZeneca, Eli Lilly and Company, Rise Therapeutics, TNF Pharmaceuticals, Incyte, UCB, and others.
Axial Spondyloarthritis Market
Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key axial spondyloarthritis companies including Janssen Pharmaceuticals, Pfizer, UCB, Amgen, Kyowa Kirin, Eli Lilly and Company, Novartis, AbbVie, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/juvenile-idiopathic-arthritis-market-is-expected-to-expand-at-a-healthy-growth-rate-of-5-6-during-the-forecast-period-20262036–delveinsight-302689243.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…